TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04775745: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Sponsor: Newave Pharmaceutical Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$8,482,320

Rescue Site Savings

+$5,592,048

Unlock Full NCT04775745 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04775745 Rescue Dossier →